Law360, New York (October 23, 2012, 9:47 PM EDT) -- Mylan Pharmaceuticals Inc. on Tuesday lost its bid to block Watson Laboratories Inc.'s production of a generic version of diabetes drug Actos while it appeals to the D.C. Circuit a Washington federal judge's Monday order directing the U.S. Food and Drug Administration to immediately approve the generic drug.
U.S. District Judge Amy Berman Jackson rejected Mylan's argument that it would be irreparably harmed by the entry into the market by Watson, which successfully challenged Mylan's market exclusivity for Actos granted by the FDA.
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.